Search

Your search keyword '"Complete Molecular Response"' showing total 115 results

Search Constraints

Start Over You searched for: Descriptor "Complete Molecular Response" Remove constraint Descriptor: "Complete Molecular Response"
115 results on '"Complete Molecular Response"'

Search Results

1. Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania.

2. Comparison of autologous and allogeneic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

3. Real world outcomes in patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation–A single institution experience

4. Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.

5. Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.

6. Complete Molecular Response due to nilotinib as III line treatment in a patient with CML and F317L point mutation of the Bcr-Abl kinase domain

7. Comparison of autologous and allogeneic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

9. THERAPEUTIC SUCCESS IN CHRONIC MYELOID LEUKAEMIA-ACCELERATED PHASE AT ONSET.

10. [Comparison of autologous versus matched sibling donor stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia]

11. Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience

12. Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation

13. Real world outcomes in patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation-A single institution experience.

14. Outcome of pediatric chronic myeloid leukemia with management focusing on the monitoring of BCR-ABL fusion gene transcript levels.

15. Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML

16. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON).

17. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

18. CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity.

19. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.

20. Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia

21. Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study

22. Serendipity: decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia

23. Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations

25. Complete molecular response induced by nilotinib in a patient previously treated with imatinib, nilotinib and dasatinib

26. Safety and efficacy of nilotinib after 10 years of interferon

27. Major molecular response induced by nilotinib as first line treatment in a LMC patient with intermediate Sokal risk

28. Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response

29. Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post–Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients

30. Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience

32. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era

33. Utility values for specific chronic myeloid leukemia chronic phase health states from the general public in the United Kingdom

34. Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)

35. Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

36. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

37. Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients

38. Imatinib (IM) discontinuation in chronic myeloid leukemia (CML): A pharmacogenetic score for patients with durable complete molecular response (CMR)

39. Frequency of BCR-ABL Transcript Types in Syrian CML Patients

40. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group

41. Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

42. [Comparison of autologous versus matched sibling donor stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia].

43. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

44. Targeted Therapies in Chronic Myeloid Leukemia

45. Nilotinib therapy after resistance to imatinib

46. Efficacy of nilotinib in a patient in non-optimal response after imatinib treatment but in reduced compliance to the new drug

47. Nilotinib therapy after resistance and intolerance to imatinib in CML patient with trisomy of the chromosome 8

48. Complete Molecular Response due to nilotinib as III line treatment in a patient with CML and F317L point mutation of the Bcr-Abl kinase domain

49. Deep molecular response in chronic myelogenous leukemia: ensuring accuracy and consistency

50. The challenge of treating elderly patients with mantle cell lymphoma

Catalog

Books, media, physical & digital resources